{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:36:58Z","timestamp":1792417018279,"version":"4.4.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K19938"],"award-info":[{"award-number":["25K19938"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K27713"],"award-info":[{"award-number":["23K27713"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Glioblastoma (GBM),\n                    <jats:italic>IDH<\/jats:italic>\n                    -wildtype, is the most common and aggressive primary brain tumor in adults. According to the 2021 WHO classification,\n                    <jats:italic>IDH<\/jats:italic>\n                    -wildtype diffuse gliomas with a\n                    <jats:italic>TERT<\/jats:italic>\n                    promoter (\n                    <jats:italic>TERT<\/jats:italic>\n                    p) mutation,\n                    <jats:italic>EGFR<\/jats:italic>\n                    amplification, or combined whole-chromosome 7 gain and 10 loss (+\u20097\/\u2212\u200910) are designated as GBM,\n                    <jats:italic>IDH<\/jats:italic>\n                    -wildtype, regardless of histological grade, and termed molecular GBM (mol-GBM). Although this redefinition has been widely adopted, the prognostic implications of mol-GBM remain uncertain. To clarify its clinical relevance, we retrospectively analyzed adult patients treated at our institution between 2010 and 2024. We identified 22 cases of\n                    <jats:italic>TERT<\/jats:italic>\n                    p-mutant mol-GBM (grade 2,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20097; grade 3,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200915) and compared them with 218 cases of\n                    <jats:italic>TERT<\/jats:italic>\n                    p-mutant histologically confirmed GBM (hist-GBM). Overall survival (OS) was assessed using Kaplan\u2013Meier analysis, log-rank test, and propensity score matching (PSM) adjusted for age, preoperative Karnofsky Performance Status, extent of resection, adjuvant therapy, and\n                    <jats:italic>MGMT<\/jats:italic>\n                    methylation status. Mol-GBM showed significantly longer OS than hist-GBM after PSM (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.019), with grade 2\u00a0mol-GBM showing particularly favorable survival (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.008). Cox regression analysis revealed mol-GBM as an independent predictor of good prognosis (hazard ratio: 0.37, 95% confidence interval: 0.22\u20130.62,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Across all\n                    <jats:italic>TERT<\/jats:italic>\n                    p-mutant GBMs, a non-contrast-enhancing (non-CE) MRI phenotype correlated with significantly longer OS than CE tumors, persisting after PSM (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.004). Within mol-GBM, an isolated\n                    <jats:italic>TERT<\/jats:italic>\n                    p mutation did not stratify OS, whereas\n                    <jats:italic>CDKN2A\/B<\/jats:italic>\n                    homozygous deletion predicted worse outcomes (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.026). DNA methylation profiling classified most mol-GBM as GBM,\n                    <jats:italic>IDH<\/jats:italic>\n                    -wildtype methylation class, and all cases clustered with GBM on t-SNE, confirming molecular proximity to GBM. Integrated methylation and RNA-seq analysis revealed\n                    <jats:italic>WIF-1<\/jats:italic>\n                    promoter hypermethylation with reduced expression in grade 3 cases. These findings suggest that histological grade 2 and the non-CE phenotype may provide exploratory prognostic information in\n                    <jats:italic>TERT<\/jats:italic>\n                    p-mutant mol-GBM, complementary to DNA methylation classification.\n                  <\/jats:p>","DOI":"10.1186\/s40478-026-02269-z","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T19:04:36Z","timestamp":1772651076000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Histological grade 2 and non-contrast-enhancing phenotype provide prognostic information complementary to DNA methylation classification in TERTp-mutant molecular glioblastomas"],"prefix":"10.1186","volume":"14","author":[{"given":"Hiroyuki","family":"Sueyoshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3181-0480","authenticated-orcid":false,"given":"Kenji","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rin","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Nakachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-ichiro","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Shinojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Mikami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7776-9086","authenticated-orcid":false,"given":"Akitake","family":"Mukasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"2269_CR1","doi-asserted-by":"publisher","first-page":"3775","DOI":"10.1038\/s41598-023-30395-4","volume":"13","author":"P Ajuyah","year":"2023","unstructured":"Ajuyah P, Mayoh C, Lau LMS, Barahona P, Wong M, Chambers H et al (2023) Histone H3-wild type diffuse midline gliomas with H3K27me3 loss are a distinct entity with exclusive EGFR or ACVR1 mutation and differential methylation of homeobox genes. Sci Rep 13:3775. https:\/\/doi.org\/10.1038\/s41598-023-30395-4","journal-title":"Sci Rep"},{"key":"2269_CR2","doi-asserted-by":"publisher","first-page":"vdae228","DOI":"10.1093\/noajnl\/vdae228","volume":"7","author":"K Aldape","year":"2025","unstructured":"Aldape K, Capper D, von Deimling A, Giannini C, Gilbert MR, Hawkins C et al (2025) cIMPACT-NOW update 9: recommendations on utilization of genome-wide DNA methylation profiling for central nervous system tumor diagnostics. Neuro-Oncol Adv 7:vdae228. https:\/\/doi.org\/10.1093\/noajnl\/vdae228","journal-title":"Neuro-Oncol Adv"},{"key":"2269_CR3","doi-asserted-by":"publisher","first-page":"397","DOI":"10.32074\/1591-951X-823","volume":"114","author":"M Antonelli","year":"2022","unstructured":"Antonelli M, Poliani PL (2022) Adult type diffuse gliomas in the new 2021 WHO Classification. Pathologica 114:397\u2013409. https:\/\/doi.org\/10.32074\/1591-951X-823","journal-title":"Pathologica"},{"key":"2269_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noz124","author":"R Appay","year":"2019","unstructured":"Appay R, Dehais C, Maurage C-A, Alentorn A, Carpentier C, Colin C et al (2019) CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro Oncol. https:\/\/doi.org\/10.1093\/neuonc\/noz124","journal-title":"Neuro Oncol"},{"key":"2269_CR5","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s00401-013-1203-9","volume":"126","author":"H Arita","year":"2013","unstructured":"Arita H, Narita Y, Takami H, Fukushima S, Matsushita Y, Yoshida A et al (2013) TERT promoter mutations rather than methylation are the main mechanism for TERT upregulation in adult gliomas. Acta Neuropathol 126:939\u2013941. https:\/\/doi.org\/10.1007\/s00401-013-1203-9","journal-title":"Acta Neuropathol"},{"key":"2269_CR6","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1093\/bioinformatics\/btu049","volume":"30","author":"MJ Aryee","year":"2014","unstructured":"Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD et al (2014) Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics 30:1363\u20131369. https:\/\/doi.org\/10.1093\/bioinformatics\/btu049","journal-title":"Bioinformatics"},{"key":"2269_CR7","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1093\/neuonc\/noaa258","volume":"23","author":"G Berzero","year":"2021","unstructured":"Berzero G, Di Stefano AL, Ronchi S, Bielle F, Villa C, Guillerm E et al (2021) IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification. Neuro Oncol 23:955\u2013966. https:\/\/doi.org\/10.1093\/neuonc\/noaa258","journal-title":"Neuro Oncol"},{"key":"2269_CR8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00401-020-02127-9","volume":"139","author":"DJ Brat","year":"2020","unstructured":"Brat DJ, Aldape K, Colman H, Figrarella-Branger D, Fuller GN, Giannini C et al (2020) cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol 139:603\u2013608. https:\/\/doi.org\/10.1007\/s00401-020-02127-9","journal-title":"Acta Neuropathol"},{"key":"2269_CR9","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00401-018-1913-0","volume":"136","author":"DJ Brat","year":"2018","unstructured":"Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB et al (2018) cIMPACT-NOW update 3: recommended diagnostic criteria for \u201cDiffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV.\u201d Acta Neuropathol 136:805\u2013810. https:\/\/doi.org\/10.1007\/s00401-018-1913-0","journal-title":"Acta Neuropathol"},{"key":"2269_CR10","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nature26000","volume":"555","author":"D Capper","year":"2018","unstructured":"Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D et al (2018) DNA methylation-based classification of central nervous system tumours. Nature 555:469\u2013474. https:\/\/doi.org\/10.1038\/nature26000","journal-title":"Nature"},{"key":"2269_CR11","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1002\/(sici)1097-0142(19980415)82:8<1550::Aid-cncr17>3.0.Co;2-3","volume":"82","author":"SW Coons","year":"1998","unstructured":"Coons SW, Pearl DK (1998) Mitosis identification in diffuse gliomas. Cancer 82:1550\u20131555. https:\/\/doi.org\/10.1002\/(sici)1097-0142(19980415)82","journal-title":"Cancer"},{"key":"2269_CR12","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1002\/1097-0142(19881115)62:10<2152::aid-cncr2820621015>3.0.co;2-t","volume":"62","author":"C Daumas-Duport","year":"1988","unstructured":"Daumas-Duport C, Scheithauer B, O\u2019Fallon J, Kelly P (1988) Grading of astrocytomas. A simple and reproducible method. Cancer 62:2152\u20132165. https:\/\/doi.org\/10.1002\/1097-0142(19881115)62","journal-title":"Cancer"},{"key":"2269_CR13","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1093\/neuonc\/noaa247","volume":"23","author":"J Dejaegher","year":"2021","unstructured":"Dejaegher J, Solie L, Hunin Z, Sciot R, Capper D, Siewert C et al (2021) DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival. Neuro Oncol 23:240\u2013250. https:\/\/doi.org\/10.1093\/neuonc\/noaa247","journal-title":"Neuro Oncol"},{"key":"2269_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/neuonc\/noac177","volume":"25","author":"R Drexler","year":"2023","unstructured":"Drexler R, Schuller U, Eckhardt A, Filipski K, Hartung TI, Harter PN et al (2023) DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients. Neuro Oncol 25:315\u2013325. https:\/\/doi.org\/10.1093\/neuonc\/noac177","journal-title":"Neuro Oncol"},{"key":"2269_CR15","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8498","author":"E Duregon","year":"2016","unstructured":"Duregon E, Bertero L, Pittaro A, Soffietti R, Rud\u00e0 R, Trevisan M et al (2016) Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas. Oncotarget. https:\/\/doi.org\/10.18632\/oncotarget.8498","journal-title":"Oncotarget"},{"key":"2269_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf070","author":"M Foltyn-Dumitru","year":"2025","unstructured":"Foltyn-Dumitru M, Banan R, Schell M, Mahmutoglu MA, Kessler T, Wick W et al (2025) Histopathological and molecular characteristics of IDH-wildtype glioblastoma without contrast enhancement: implications for clinical outcomes. Neuro Oncol. https:\/\/doi.org\/10.1093\/neuonc\/noaf070","journal-title":"Neuro Oncol"},{"key":"2269_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00401-021-02337-9","volume":"142","author":"K Fujimoto","year":"2021","unstructured":"Fujimoto K, Arita H, Satomi K, Yamasaki K, Matsushita Y, Nakamura T et al (2021) TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma. Acta Neuropathol 142:323\u2013338. https:\/\/doi.org\/10.1007\/s00401-021-02337-9","journal-title":"Acta Neuropathol"},{"key":"2269_CR18","doi-asserted-by":"publisher","first-page":"5658","DOI":"10.1158\/0008-5472.CAN-12-0953","volume":"72","author":"A Gong","year":"2012","unstructured":"Gong A, Huang S (2012) FoxM1 and Wnt\/beta-catenin signaling in glioma stem cells. Cancer Res 72:5658\u20135662. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-0953","journal-title":"Cancer Res"},{"key":"2269_CR19","doi-asserted-by":"publisher","first-page":"1200815","DOI":"10.3389\/fonc.2023.1200815","volume":"13","author":"X Guo","year":"2023","unstructured":"Guo X, Gu L, Li Y, Zheng Z, Chen W, Wang Y et al (2023) Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumors. Front Oncol 13:1200815. https:\/\/doi.org\/10.3389\/fonc.2023.1200815","journal-title":"Front Oncol"},{"key":"2269_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci8010005","author":"A Haj","year":"2017","unstructured":"Haj A, Doenitz C, Schebesch KM, Ehrensberger D, Hau P, Putnik K et al (2017) Extent of resection in newly diagnosed glioblastoma: impact of a specialized neuro-oncology care center. Brain Sci. https:\/\/doi.org\/10.3390\/brainsci8010005","journal-title":"Brain Sci"},{"key":"2269_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215375","author":"G Hutarew","year":"2022","unstructured":"Hutarew G, Holzl D, Schiefer T, Langwieder CK, Alinger-Scharinger B, Schlicker HU et al (2022) Methylome profiling of PD-L1-expressing glioblastomas shows enrichment of post-transcriptional and RNA-associated gene regulation. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14215375","journal-title":"Cancers (Basel)"},{"key":"2269_CR22","doi-asserted-by":"crossref","unstructured":"Hsieh JC, Kodjabachian L, Rebbert ML, Rattner A, Smallwood PM, Samos CH, Nusse R, Dawid IB, Nathans J (1999) Anewsecreted protein that bindstoWntproteins and inhibits theiractivites. letters to nature. Nature 398(6726):431\u20136","DOI":"10.1038\/18899"},{"key":"2269_CR23","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2353\/jmoldx.2006.060012","volume":"8","author":"J Jeuken","year":"2006","unstructured":"Jeuken J, Cornelissen S, Boots-Sprenger S, Gijsen S, Wesseling P (2006) Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors. J Mol Diagn 8:433\u2013443. https:\/\/doi.org\/10.2353\/jmoldx.2006.060012","journal-title":"J Mol Diagn"},{"key":"2269_CR24","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/neuonc\/noad160","volume":"26","author":"P Karschnia","year":"2024","unstructured":"Karschnia P, Dietrich J, Bruno F, Dono A, Juenger ST, Teske N et al (2024) Surgical management and outcome of newly diagnosed glioblastoma without contrast enhancement (low-grade appearance): a report of the RANO resect group. Neuro Oncol 26:166\u2013177. https:\/\/doi.org\/10.1093\/neuonc\/noad160","journal-title":"Neuro Oncol"},{"key":"2269_CR25","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1158\/1078-0432.CCR-23-0926","volume":"29","author":"T Kessler","year":"2023","unstructured":"Kessler T, Schrimpf D, Doerner L, Hai L, Kaulen LD, Ito J et al (2023) Prognostic markers of DNA methylation and next-generation sequencing in progressive glioblastoma from the EORTC-26101 trial. Clin Cancer Res 29:3892\u20133900. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0926","journal-title":"Clin Cancer Res"},{"key":"2269_CR26","doi-asserted-by":"publisher","first-page":"335","DOI":"10.21873\/anticanres.15490","volume":"42","author":"M Kim","year":"2022","unstructured":"Kim M, Yoo J, Chang JH, Kim SH (2022) Association of MGMT gene promoter methylation with clinicopathological parameters in patients with wild-type IDH glioblastoma. Anticancer Res 42:335\u2013341. https:\/\/doi.org\/10.21873\/anticanres.15490","journal-title":"Anticancer Res"},{"key":"2269_CR27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/labinvest.2015.140","volume":"96","author":"Y Lee","year":"2016","unstructured":"Lee Y, Lee JK, Ahn SH, Lee J, Nam DH (2016) WNT signaling in glioblastoma and therapeutic opportunities. Lab Invest 96:137\u2013150. https:\/\/doi.org\/10.1038\/labinvest.2015.140","journal-title":"Lab Invest"},{"key":"2269_CR28","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"key":"2269_CR29","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/bpa.12832","volume":"30","author":"DN Louis","year":"2020","unstructured":"Louis DN, Wesseling P, Aldape K, Brat DJ, Capper D, Cree IA et al (2020) cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol 30:844\u2013856. https:\/\/doi.org\/10.1111\/bpa.12832","journal-title":"Brain Pathol"},{"key":"2269_CR30","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15:550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8","journal-title":"Genome Biol"},{"key":"2269_CR31","first-page":"2579","volume":"9","author":"L Maaten","year":"2008","unstructured":"Maaten L (2008) Visualizing data using t-SNE. J Mach Learn Res 9:2579\u20132605","journal-title":"J Mach Learn Res"},{"key":"2269_CR32","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.83606","author":"M Moradi Marjaneh","year":"2023","unstructured":"Moradi Marjaneh M, Kirk EP, Patrick R, Alankarage D, Humphreys DT, Del Monte-Nieto G et al (2023) Quantitative trait and transcriptome analysis of genetic complexity underpinning cardiac interatrial septation in mice using an advanced intercross line. Elife. https:\/\/doi.org\/10.7554\/eLife.83606","journal-title":"Elife"},{"key":"2269_CR33","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1002\/ijc.26499","volume":"131","author":"S Mulholland","year":"2012","unstructured":"Mulholland S, Pearson DM, Hamoudi RA, Malley DS, Smith CM, Weaver JM et al (2012) MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations. Int J Cancer 131:1104\u20131113. https:\/\/doi.org\/10.1002\/ijc.26499","journal-title":"Int J Cancer"},{"key":"2269_CR34","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s00401-024-02773-3","volume":"148","author":"LP Priesterbach-Ackley","year":"2024","unstructured":"Priesterbach-Ackley LP, Cordier F, de Witt Hamer P, Snijders TJ, Robe PA, Kusters B et al (2024) Diffuse, IDH-wildtype gliomas in adults with minimal histological change and isolated TERT promoter mutation: not simply CNS WHO grade 4. Acta Neuropathol 148:12. https:\/\/doi.org\/10.1007\/s00401-024-02773-3","journal-title":"Acta Neuropathol"},{"key":"2269_CR35","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1093\/neuonc\/noac108","volume":"24","author":"FL Ricklefs","year":"2022","unstructured":"Ricklefs FL, Drexler R, Wollmann K, Eckhardt A, Heiland DH, Sauvigny T et al (2022) DNA methylation subclass receptor tyrosine kinase II (RTK II) is predictive for seizure development in glioblastoma patients. Neuro Oncol 24:1886\u20131897. https:\/\/doi.org\/10.1093\/neuonc\/noac108","journal-title":"Neuro Oncol"},{"key":"2269_CR36","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1523\/JNEUROSCI.5074-07.2008","volume":"28","author":"K Sakurai","year":"2008","unstructured":"Sakurai K, Osumi N (2008) The neurogenesis-controlling factor, Pax6, inhibits proliferation and promotes maturation in murine astrocytes. J Neurosci 28:4604\u20134612. https:\/\/doi.org\/10.1523\/JNEUROSCI.5074-07.2008","journal-title":"J Neurosci"},{"key":"2269_CR37","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1038\/s41375-023-01966-1","volume":"37","author":"L Salz","year":"2023","unstructured":"Salz L, Seitz A, Schafer D, Franzen J, Holzer T, Garcia-Prieto CA et al (2023) Culture expansion of CAR T cells results in aberrant DNA methylation that is associated with adverse clinical outcome. Leukemia 37:1868\u20131878. https:\/\/doi.org\/10.1038\/s41375-023-01966-1","journal-title":"Leukemia"},{"key":"2269_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3171\/2011.2.jns10998","volume":"115","author":"N Sanai","year":"2011","unstructured":"Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS (2011) An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 115:3\u20138. https:\/\/doi.org\/10.3171\/2011.2.jns10998","journal-title":"J Neurosurg"},{"key":"2269_CR39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00401-018-1849-4","volume":"136","author":"M Shirahata","year":"2018","unstructured":"Shirahata M, Ono T, Stichel D, Schrimpf D, Reuss DE, Sahm F et al (2018) Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathol 136:153\u2013166. https:\/\/doi.org\/10.1007\/s00401-018-1849-4","journal-title":"Acta Neuropathol"},{"key":"2269_CR40","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/neuonc\/noz200","volume":"22","author":"CMS Tesileanu","year":"2020","unstructured":"Tesileanu CMS, Dirven L, Wijnenga MMJ, Koekkoek JAF, Vincent A, Dubbink HJ et al (2020) Survival of diffuse astrocytic glioma, IDH1\/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Neuro Oncol 22:515\u2013523. https:\/\/doi.org\/10.1093\/neuonc\/noz200","journal-title":"Neuro Oncol"},{"key":"2269_CR41","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.70035","author":"P Wesseling","year":"2025","unstructured":"Wesseling P, Capper D, Reifenberger G, Sarkar C, Hawkins C, Perry A et al (2025) cIMPACT-NOW update 11: proposal on adaptation of diagnostic criteria for IDH- and H3-wildtype diffuse high-grade gliomas and for posterior fossa ependymal tumors. Brain Pathol. https:\/\/doi.org\/10.1111\/bpa.70035","journal-title":"Brain Pathol"},{"key":"2269_CR42","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s00401-017-1781-z","volume":"134","author":"MMJ Wijnenga","year":"2017","unstructured":"Wijnenga MMJ, Dubbink HJ, French PJ, Synhaeve NE, Dinjens WNM, Atmodimedjo PN et al (2017) Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification. Acta Neuropathol 134:957\u2013959. https:\/\/doi.org\/10.1007\/s00401-017-1781-z","journal-title":"Acta Neuropathol"},{"key":"2269_CR43","doi-asserted-by":"publisher","first-page":"vdad075","DOI":"10.1093\/noajnl\/vdad075","volume":"5","author":"MMJ Wijnenga","year":"2023","unstructured":"Wijnenga MMJ, Maas SLN, van Dis V, Tesileanu CMS, Kros JM, Dirven L et al (2023) Glioblastoma lacking necrosis or vascular proliferations: different clinical presentation but similar outcome, regardless of histology or isolated TERT promoter mutation. Neuro-Oncol Adv 5:vdad075. https:\/\/doi.org\/10.1093\/noajnl\/vdad075","journal-title":"Neuro-Oncol Adv"},{"key":"2269_CR44","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1007\/s11481-012-9359-y","volume":"7","author":"K Zhang","year":"2012","unstructured":"Zhang K, Zhang J, Han L, Pu P, Kang C (2012) Wnt\/beta-catenin signaling in glioma. J Neuroimmune Pharmacol 7:740\u2013749. https:\/\/doi.org\/10.1007\/s11481-012-9359-y","journal-title":"J Neuroimmune Pharmacol"},{"key":"2269_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-29-26","author":"Z Yang","year":"2010","unstructured":"Yang Z, Wang Y, Fang J, Chen F, Liu J, Wu J (2010) Expression and aberrant promoter methylation of Wnt inhibitory factor-1 in human astrocytomas. J Exp Clin Cancer Res. https:\/\/doi.org\/10.1186\/1756-9966-29-26","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-026-02269-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-026-02269-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-026-02269-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:22:11Z","timestamp":1781637731000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40478-026-02269-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2269"],"URL":"https:\/\/doi.org\/10.1186\/s40478-026-02269-z","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"9 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Kumamoto University (Approval No. 1760).Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}